LEGAL SUBJECT

Intellectual Property Law

Judgment analyses where this is the main or secondary subject.

Latest analyses

30 ARTICLES
Synergistic pharmaceutical combinations of independent active agents are patentable products and not excluded methods of treatment. SUMMARY 1. Facts: The Appellant challenged an order by the Deputy Controller of Patents refusing an application for a pharmaceutical combination (Encorafenib, an EGFR inhibitor, and an optional PI3K-α inhibitor). The Patent Office rejected the application on grounds of lack of inventive step (Section 2(1)(ja)), non-patentability as a "new form of a known substance" (Section 3(d)), and for being a "method of treatment" (Section 3(i)). 2. Issues: * Whether a combination of known independent active pharmaceutical agents (APAs) constitutes a "method of treatment" under Section 3(i). * Whether Section 3(d) applies to a combination of distinct active ingredients. * Whether the combination demonstrated technical advancement over cited prior art (D1-D4). 3. Court’s Reasoning: * Section 3(i): The Court held that Claim 1 was a product claim for a "pharmaceutical combination," not a process. Functional descriptors like "simultaneous or sequential administration" describe how the product is used but do not transform a product claim into a method of treatment. Working examples in the specification demonstrate feasibility but do not define the legal scope of the claims. * Section 3(d): Following established precedent, the Court ruled that Section 3(d) typically applies to new forms/derivatives of a *single* known substance. A combination of two or more separate active drugs (each with distinct chemical identities) does not fall under Section 3(d) as they are not "derivatives" of each other. * Inventive Step: The Court found the Controller’s analysis flawed. The cited prior arts (D1-D4) did not disclose the specific combination of the claimed inhibitors. Furthermore, the clinical data provided in the specification demonstrated significant tumor regression (synergy) which was not anticipated by the prior art. 4. Conclusion: The High Court set aside the impugned order, holding the findings on Sections 3(i), 3(d), and 2(1)(ja) unsustainable. The matter was remanded to the Controller for fresh consideration on merits within six months.. Array Biopharma Inc vs Deputy Controller Of Patents And Designs. Delhi High Court. LawLens

Delhi High Court

Synergistic pharmaceutical combinations of independent active agents are patentable products and not excluded methods of treatment. SUMMARY 1. Facts: The Appellant challenged an order by the Deputy Controller of Patents refusing an application for a pharmaceutical combination (Encorafenib, an EGFR inhibitor, and an optional PI3K-α inhibitor). The Patent Office rejected the application on grounds of lack of inventive step (Section 2(1)(ja)), non-patentability as a "new form of a known substance" (Section 3(d)), and for being a "method of treatment" (Section 3(i)). 2. Issues: * Whether a combination of known independent active pharmaceutical agents (APAs) constitutes a "method of treatment" under Section 3(i). * Whether Section 3(d) applies to a combination of distinct active ingredients. * Whether the combination demonstrated technical advancement over cited prior art (D1-D4). 3. Court’s Reasoning: * Section 3(i): The Court held that Claim 1 was a product claim for a "pharmaceutical combination," not a process. Functional descriptors like "simultaneous or sequential administration" describe how the product is used but do not transform a product claim into a method of treatment. Working examples in the specification demonstrate feasibility but do not define the legal scope of the claims. * Section 3(d): Following established precedent, the Court ruled that Section 3(d) typically applies to new forms/derivatives of a *single* known substance. A combination of two or more separate active drugs (each with distinct chemical identities) does not fall under Section 3(d) as they are not "derivatives" of each other. * Inventive Step: The Court found the Controller’s analysis flawed. The cited prior arts (D1-D4) did not disclose the specific combination of the claimed inhibitors. Furthermore, the clinical data provided in the specification demonstrated significant tumor regression (synergy) which was not anticipated by the prior art. 4. Conclusion: The High Court set aside the impugned order, holding the findings on Sections 3(i), 3(d), and 2(1)(ja) unsustainable. The matter was remanded to the Controller for fresh consideration on merits within six months.

The Appellant filed Indian Patent Application No. 450/DELNP/2015 for a pharmaceutical combination comprising a B-Raf inhibitor (Encorafenib), an EGFR inhibitor (Cetuximab/Erlotinib), and optionally a PI3K-alpha inhibi...2 MIN READ